Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

An outpatient nephrology consultation is requested for a renal transplant recipient who developed acute kidney injury and neurologic symptoms. The patient, who received a deceased-donor kidney six months prior due to IgA nephropathy, has been maintained on a regimen of tacrolimus, mycophenolate mofetil, and prednisone. Fourteen days ago, oral fluconazole therapy was initiated for persistent oropharyngeal candidiasis.

Currently, the patient complains of new-onset bilateral hand tremors and intermittent headaches. Vital signs show a blood pressure of 152/92 mmHg and a pulse of 82/min. Examination demonstrates a fine postural tremor but no allograft tenderness.

Laboratory analysis reveals a serum creatinine of 1.9 mg/dL and a blood urea nitrogen of 34 mg/dL. Baseline serum creatinine two weeks prior was 1.1 mg/dL.

Which of the following is the most appropriate next step in monitoring and adjusting this patient's treatment plan?

  1. A
    Schedule an ultrasound-guided percutaneous allograft biopsy
  2. B
    Continue the current regimen and prescribe a beta-blocker for the tremors
  3. Obtain a serum tacrolimus trough level and reduce the tacrolimus dosageAnswer
  4. D
    Order a renal allograft Doppler ultrasound
  5. E
    Discontinue mycophenolate mofetil and initiate intravenous methylprednisolone

Answer

Obtain a serum tacrolimus trough level and reduce the tacrolimus dosage
The correct response addresses the pharmacokinetic interaction between fluconazole and tacrolimus. Fluconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system. Tacrolimus, a calcineurin inhibitor, is extensively metabolized by CYP3A4. Concomitant administration leads to significantly elevated serum tacrolimus concentrations. Toxicity classically presents with acute kidney injury (due to dose-dependent afferent arteriolar vasoconstriction), new-onset hypertension, and neurotoxic manifestations such as fine resting tremors and headaches. The most appropriate initial step in monitoring and management is to obtain a serum tacrolimus trough level to confirm the toxicity and immediately reduce the tacrolimus dosage to prevent further organ damage.

Step-by-Step Solution

1
Analyze the medication list and recent changes.
The patient takes tacrolimus (a CYP3A4 substrate) and was recently started on fluconazole (a potent CYP3A4 inhibitor).
Identifying drug-drug interactions is critical when evaluating new symptoms in transplant patients.
2
Correlate the pharmacokinetic interaction with the clinical presentation.
CYP3A4 inhibition leads to supratherapeutic tacrolimus levels, which cause classic calcineurin inhibitor toxicity: acute kidney injury (via afferent arteriolar vasoconstriction), new-onset hypertension, and neurotoxicity (tremors, headaches).
The combination of AKI and neurologic symptoms points away from isolated structural renal issues and toward systemic drug toxicity.
3
Determine the safest and most effective initial management step.
The clinician must verify the elevated tacrolimus level via a serum trough and preemptively reduce the dosage to halt ongoing toxicity.
Non-invasive monitoring and dose adjustments must precede invasive diagnostics (like biopsy) when a clear, reversible toxicological cause is present.

Key Concept

Monitoring Calcineurin Inhibitor Toxicity due to CYP3A4 Interactions
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic